Results 181 to 190 of about 14,491 (226)

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Journal of Thoracic Oncology, 2019
INTRODUCTION At the prior data cutoff (February 9, 2017) the ALEX trial showed superior investigator-assessed progression-free survival (PFS) for alectinib versus crizotinib in untreated, anaplastic lymphoma kinase (ALK)-positive, advanced NSCLC (hazard ...
Rafal Dziadziuszko, Solange Peters, Tony Mok   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Alectinib

Reactions Weekly, 2023
  +9 more sources

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

New England Journal of Medicine
BACKGROUND Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non-small-cell lung cancer (NSCLC).
Yi-Long Wu, R. Dziadziuszko, Jin Seok Ahn, F. Barlesi, M. Nishio, Dae Ho Lee, Jong-Seok Lee, Wenzhao Zhong, H. Horinouchi, Weimin Mao, Maximilian Hochmair, F. de Marinis, M. R. Migliorino, Igor Bondarenko, Shun Lu, Qun Wang, Tania Ochi Lohmann, Tingting Xu, A. Cardona, T. Ruf, Johannes Noe, Benjamin J Solomon   +21 more
semanticscholar   +1 more source

Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316).

Journal of Clinical Oncology
8015 Background: Stage III Non-Small Cell Lung Cancer (NSCLC) is a heterogeneous group of tumors with a wide spectrum of clinical presentations and no single definitive therapeutic approach.
A. Leonetti, Luca Boni, L. Gnetti, D. Cortinovis, G. Pasello, Francesca Mazzoni, Alessandra Bearz, F. Gelsomino, F. Passiglia, S. Pilotto, G. Metro, A. Delmonte, F. Cecere, Federica Bertolini, L. Toschi, H. S. Soto Parra, S. Ricciardi, E. Bria, Michele Tognetto, M. Tiseo   +19 more
semanticscholar   +1 more source

Alectinib-Loaded Chitosan–Alginate Nanoparticles: A Novel Synthesis Method with In Vitro and In Vivo Evaluations

Pharmaceutics
Background/Objectives: Non-small cell lung cancer (NSCLC) constitutes over 84% of all lung cancer cases and is a leading cause of cancer-related mortality globally.
Tha'er Ata, I. Al-Ani, Nida Karameh, Mahmood R. Atta, W. A. Dayyih   +4 more
semanticscholar   +1 more source

Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

Nature Communications
Up to 25% of patients with ALK-rearranged non-small cell lung cancer (NSCLC) experience disease progression within the first year of targeted therapy.
Oscar Arrieta, L. Lara-Mejía, Eduardo Rios-Garcia, E. Caballé-Pérez, L. Cabrera-Miranda, M. Ramos-Ramírez, David Dávila-Dupont, A. F. Cardona, G. Cruz-Rico, J. Remon, Alexandra Garcilazo-Reyes, Rafael Rosell   +11 more
semanticscholar   +1 more source

First Report of SPECC1L::ALK Fusion in Medullary Thyroid Carcinoma with Remarkable Response to Alectinib

Thyroid
Background: Rearrangements of the ALK gene are rare in medullary thyroid carcinoma (MTC), with limited data on the efficacy of ALK inhibitors in this context. Novel fusions, such as SPECC1L::ALK, have not been extensively studied.
H. Bischoff, Antonin Fattori, F. Moinard-Butot, Olivier Schneegans, Pablo Diaz, Damien Reita, Valérie Rimelen, Anna Voegeli, Laura Bender   +8 more
semanticscholar   +1 more source

Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada

PharmacoEconomics (Auckland)
For patients with resected non-small cell lung cancer (NSCLC), the risk of disease recurrence and progression is associated with a substantial humanistic, clinical, and economic burden.
Nick Jovanoski, S. Vaselenak, Andrew Hogan, Jasmine Turki, Q. Chu   +4 more
semanticscholar   +1 more source

The role of BIM gene deletion in ALK-mutated Non-small cell lung cancer treated with alectinib

Clinical and Experimental Medicine (Testo stampato)
Alectinib, as a first-line therapeutic option for advanced ALK mutation-positive non-small-cell lung cancer (NSCLC), is now widely used in the clinic. However, the associated mechanisms of resistance are unknown.
Shuang Hou, Weijun Zhang, Wei Pang, Haiqun Xia, Jinyun Tan, Qingfang Huang, Ping Yang   +6 more
semanticscholar   +1 more source

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient

Frontiers in Pharmacology
Background Anaplastic lymphoma kinase (ALK) rearrangements account for approximately 3%–5% of non-small cell lung cancer (NSCLC), and the echinoderm microtubule-associated protein-like 4 gene (EML4) and ALK fusion (EML4-ALK) is the most common ALK ...
Kaili Huang, Wen Li, Yinyin Xue, Lei Peng, Qiang Wu, Qinghua Zhou   +5 more
semanticscholar   +1 more source